Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. May 28, 2013; 19(20): 3052-3061
Published online May 28, 2013. doi: 10.3748/wjg.v19.i20.3052
Published online May 28, 2013. doi: 10.3748/wjg.v19.i20.3052
Table 2 Evaluation of overall survival and disease-free survival
| Cohort | α | Ω | AP, mo | OS, mo | DFS, mo | OS/AP % | DFS/OS % |
| 2007 | 16 | 3 | 54.00 | 50.90 | 46.90 | 94.28 | 92.14 |
| 2008 | 22 | 3 | 42.90 | 39.30 | 34.90 | 91.40 | 89.01 |
| 2009 | 18 | 2 | 30.80 | 29.40 | 22.60 | 95.53 | 76.97 |
| 2010 | 13 | 0 | 17.40 | 17.40 | 15.30 | 100.00 | 87.93 |
| 2011 | 11 | 0 | 6.30 | 6.30 | 5.60 | 100.00 | 88.79 |
| Total | 80 | 8 | 29.80 | 27.90 | 23.90 | 93.45 | 85.88 |
- Citation: Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V. Neoadjuvant-intensified treatment for rectal cancer: Time to change? World J Gastroenterol 2013; 19(20): 3052-3061
- URL: https://www.wjgnet.com/1007-9327/full/v19/i20/3052.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i20.3052